Peripheral markers of serotonergic and noradrenergic function in post- pubertal, caucasian males with autistic disorder

Neuropsychopharmacology

Volumn 22, Issue 3, 2000, Pages 275-283

  Croonenberghs, Jan ^a   Delmeire, Laure ^b   Verkerk, Robert ^c   Lin, Ai Hua ^b,c   Meskal, Anisa ^c   Neels, Hugo ^c   Van Der Planken, Marc ^e   Scharpe, Simon ^c   Deboutte, Dirk ^a   Pison, Greet ^d   Maes, Michael ^b,f,g,h  

^a University Child and Adolescent Psychiatry Antwerp   (Belgium)

^b Clinical Research Center for Mental Health of Antwerp   (Belgium)

^c Department of Medical Biochemistry ^*  (Belgium)

^d UNIVERSITY OF ANTWERP   (Belgium)

^e ANTWERP UNIVERSITY HOSPITAL   (Belgium)

^f VANDERBILT UNIVERSITY   (United States)

^g IRCCS ISTITUTO CENTRO SAN GIOVANNI DI DIO FATEBENEFRATELLI   (Italy)

^h MAASTRICHT UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

Age; Autism; Norepinephrine; Paroxetine binding; Serotonin; Serotonin transporter; Tryptophan; Tyrosine

Indexed keywords

ADRENALIN; DOPAMINE; NORADRENALIN; SEROTONIN; TRYPTOPHAN; TYROSINE;

ADOLESCENT; ADULT; ARTICLE; AUTISM; CAUCASIAN; CLINICAL ARTICLE; CORRELATION FUNCTION; HUMAN; MALE; NORADRENERGIC SYSTEM; PATHOPHYSIOLOGY; PRIORITY JOURNAL; SCHOOL CHILD; SEROTONINERGIC SYSTEM;

ADOLESCENT; AUTISTIC DISORDER; BELGIUM; BIOLOGICAL MARKERS; CHILD; DOPAMINE; EPINEPHRINE; EUROPEAN CONTINENTAL ANCESTRY GROUP; HUMANS; HYDROXYINDOLEACETIC ACID; INTELLIGENCE; MALE; NETHERLANDS; NOREPINEPHRINE; PAROXETINE; PUBERTY; SEROTONIN; TRYPTOPHAN; TYROSINE; YOHIMBINE;

EID: 17144444473     PISSN: 0893133X     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0893-133X(99)00131-1     Document Type: Article

References (63)

1. Diagnostic and Statistical Manual of Mental Disorders. 3rd ed:1987;American Psychiatric Association, Washington, DC.
2. Diagnostic and Statistical Manual of Mental Disorders. 4th ed:1994;American Psychiatric Association, Washington, DC.
3. Barthelemy C., Bruneau N., Cottet-Eymard J.M., Domenech-Jouve J., Garreau B., Lelord G., Muh J.P., Peyrin L. Urinary free and conjugated catecholamine and metabolites in autistic children. J Autism Dev Disord. 18:1988;585-591.
4. 3H]-5-HT uptake. Effect of administration of various antidepressant treatments Neuropharmacology. 32:1993;737-743.
5. Chugani D.C., Muzik O., Rothermel R., Behen M., Chakraborty P., Mangner T., da Silva E.A., Chugani H.T. Altered serotonin synthesis in the dentatothalamocortical pathway in autistic boys. Ann Neurol. 42:1997;666-669.
6. Chugani D.C., Muzik O., Behen M., Rothermel R., Janisse J.J., Lee J., Chugani H.T. Developmental changes in brain serotonin synthesis capacity in autistic and nonautistic children. Ann Neurol. 45:1999;287-295.
7. Cook E.H., Leventhal B.L., Heller W., Metz J., Wainwright M., Freedman D.X. Autistic children and their first-degree relatives. Relationships between serotonin and norepinephrine levels and intelligence J Neuropsych Clin Neurosci. 2:1990;268-274.
8. Cook E., Arora R., Anderson G., Berry-Kravis E., Yan S.-Y., Yeoh H., Sklena P., Charak D., Leventhal B. Platelet serotonin studies in hyperserotonemic relatives of children with autistic disorder. Life Sci. 52:1993;2005-2015.
9. Cook E., Leventhal B.L. The serotonin system in autism. Curr Opin Pediatr. 8:1996;348-354.
10. Cook E.H., Chourchesne R., Lord C., Cox N.J., Yan S., Lincoln A., Haas R., Courchesne E., Leventhal B.L. Evidence of Linkage between the serotonin transporter and autistic disorder. Mol Psychiatry. 2:1997;247-250.
11. D'Eufemia P., Finocchiaro R., Celli M., Viozzi L., Monteleone D., Giardini O. Low serum tryptophan to large amino acids ratio in idiopathic infantile autism. Biomed Pharmacother. 49:1995;288-292.
12. D'Hondt P., Maes M., Leysen J., Gommeren W., Scharpe S., Cosyns P. Seasonal variation in paroxetine binding to platelets in normal volunteers. Relationships to climatic factors Neuropsychopharmacology. 5:1996;187-198.
13. Fernstrom J.D. Tryptophan availability and serotonin synthesis in rat brain. Effects of experimental diabetes Schlossberger H.G., Kochen W., Linzen B., Steinhart H. Progress in Tryptophan and Serotonin Research. 1984;161-172 Walter de Gruyter, New York, NY.
14. Fichtner C.G., Arora R.C., O'Connor F.L., Crayton J.W. Platelet paroxetine binding and fluoxetine pharmacotherapy in posttraumatic stress disorder. Preliminary observations on a possible predictor of clinical treatment response Life Sci. 54:1994;39-44.
15. Garnier C., Comoy E., Barthelemy C., Leddet I., Garreau B., Muh J.P., Lelord G. Dopamine-betahyroxylase and homovanillic acid in autistic children. J Autism Dev Disord. 16:1986;23-29.
16. Gillberg C., Svennerholm L. CSF monoamines in autistic syndromes and other pervasive developmental disorders of early childhood. Br J Psychiatry. 151:1987;89-94.
17. Habert E., Graham D., Tahraoui L., Claustre Y., Langer S. Characterization of [3H]-paroxetine binding to rat cortical membranes. Eur J Pharmacol. 118:1985;107-114.
18. Hamberger A., Gillberg C., Palm A., Hagberg B. Elevated CSF glutamate in Rett syndrome. Neuropediatrics. 23:1982;212-213.
19. Hanley H.G., Stahl S.M., Freeman D.X. Hyperserotonemia and amine metabolites in autistic and retarded children. Arch Gen Psychiatry. 34:1977;521-531.
20. Hieble J.P., Bondinell W.E., Ruffolo R.R. α- and β-adrenoceptors. From the gene to the clinic. I. Molecular biology and adrenoceptor classification J Med Chem. 38:1995;3415-3444.
21. Hoffman B.B., DeLean A., Wood C.L., Schocken D.D., Lefkowitz R.J. Alpha-adrenergic subtypes. quantitative assessment by ligand binding Life Sci. 24:1979;1739-1746.
22. Hoshino Y., Yamamoto T., Kaneko M., Kumashiro H. Plasma free tryptophan concentration in autistic children. Brain Dev. 8:1986;424-427.
23. Jackson M.J., Garrod P.J. Plasma zinc, copper and amino acid levels in the blood of autistic children. J Autism Dev Disord. 8:1978;203-208.
24. Johnson R.J., Wiersema V., Kraft I.A. Hair amino acids in childhood autism. J Autism Child Schizophr. 4:1974;187-188.
25. Klauck S.M., Poustka F., Benner A., Lesch K.P., Poustka A. Serotonin transporter (5-HTT) gene variants associated with autism? Human Mol Genet. 6(13):1997;2233-2238.
26. Lake C.R., Ziegler M.G., Murphy D.L. Increased norepinephrine levels and decreased dopamine-beta-hydroxylase activity and primary autism. Arch Gen Psychiatry. 34:1977;553-556.
27. Launay J.M., Bursztejn C., Ferrari P., Dreux C., Braconnier A., Zarifian E., Lancrenon S., Fermanian J. Catecholamine metabolism in infantile autism. A controlled study of 22 autistic children J Autism Dev Disord. 17:1987;333-347.
28. Leboyer M., Bouvard M.P., Launay J.M. A double-blind study of naltrexone in infantile autism. J Autism Dev Disord. 22:1992;309-319. [Brief report].
29. Lesch K.P., Wolozin B.L., Murphy D.L., Reiderer P. Primary structure of the human platelet serotonin uptake site. Identity with the brain serotonin transporter J Neurochem. 60:1993;2319-2322.
30. Leventhal B.L., Cook E.H. Jr., Morford M., Ravitz A., Freedman D.X. Relationships of whole blood serotonin and plasma norepinephrine within families. J Autism Dev Disord. 20:1990;499-511.
31. Limberger N., Funk L., Trendelenburg A.U., Starke K. Subclassification of presynaptic a2-adrenoceptors. a2-autoreceptors in rabbit atria and kidney Naunyn-Schmiedeberg's Arch Pharmacol. 352:1995;31-42.
32. Maes M., Scharpe S., Cosyns P., Neels H., Stevens W., Bridts C., Thompson P., DeClerck L., D'Hondt P., DeMeyer F., Ranjan R., Meltzer H.Y., Peeters D., Wouters A., Cooreman W. Components of biological variation in serum activity of dipeptidyl peptidase IV and prolyl endopeptidase in normal man. Clin Chem. 40:1994;1686-1691.
33. Maes M., Scharpe S., Cosyns P., Neels H., Stevens W., Bridts C., Thompson P., DeClerck L., D'Hondt P., DeMeyer F., Ranjan R., Meltzer H.Y., Peeters D., Wouters A., Cooreman W. Components of biological variation, including seasonality in plasma L-tryptophan and competing amino-acids in man. Relationships to serum total protein, climatic variables and violent suicide occurrence Arch Gen Psychiatry. 52:1995;937-945.
34. Maes M., Wauters A., Verkerk R., Neels H., van Gastel A., Cosyns P., Scharpe S., Desnyder R. Lower L-tryptophan availability in depression. A marker of a more generalized disorder in protein metabolism Neuropsychopharmacology. 15:1996;243-251.
35. Maes M., van Gastel A., Delmeire L., Gommeren W., Leysen J. Decreased α2 receptor binding sites on platelets of depressed patients. Effects of tricyclic antidepressants and SSRIs Biol Psychiatry. 45:1998;278-284.
36. Maes M., Lin A., Verkerk R., Delmeire L., van Gastel A., Gommeren W., Leysen J., Scharpe S. Serotonergic and noradrenergic markers of posttraumatic stress disorder. Lower affinity of platelet paroxetine and alpha-2 binding sites and increased plasma tyrosine availability to the brain Neuropsychopharmacology. 20:1999;188-197.
37. Martineau J., Barthelemy C., Jouve J., Muh J.P., Lelord G. Monoamines (serotonin and catecholamines) and their derivatives in infantile autism. Age-related changes and drug effects Dev Med Child Neurol. 34:1992;593-603.
38. McBride P.A., Tierney H., DeMeo M., Chen J.S., Mann J.J. Effects of age and gender on CNS serotonergic responsivity in normal adults. Biol Psychiatry. 27:1990;1143-1155.
39. McBride P.A., Anderson G.M., Hertzig M.E., Snow M.E., Thompson S.M., Khait V.D., Shapiro T., Cohen D.J. Effects of diagnosis, race, and puberty on platelet serotonin levels in autism and mental retardation. J Am Acad Child Adolesc Psychiatry. 37:1998;767-776.
40. McDougle C.J., Naylor S.T., Cohen D.J., Aghajanian G.K., Heninger G.R., Price L.H. Effects of tryptophan depletion in drug-free adults with autistic disorder. Arch Gen Psychiatry. 53:1996;993-1000. a.
41. McDougle C.J., Naylor S.T., Cohen D.J., Volkmar F.R., Heninger G.R., Price L.H. A double-blind, placebo-controlled study of fluvoxamine in adults with autistic disorder. Arch Gen Psychiatry. 53:1996;1001-1008. b.
42. 3H]-imipramine to human platelet membranes. Eur J Pharmacol. 96:1983;303-309.
43. Minderaa R., Anderson G.M., Volkmar F.R., Harcherick D., Akkerhuis G.W., Cohen D.I. Whole blood serotonin and tryptophan in autism. Temporal stability and effects of medication J Autism Dev Disord. 19:1989;129-136.
44. Minderaa R., Anderson G.M., Volkmar F.R., Akkerhuis G.W., Cohen D.I. Noradrenergic and adrenergic functioning in autism. Biol Psychiatry. 36:1994;237-241.
45. Moir A.T.B., Eccleston D. The effect of precursor loading in the cerebral metabolism of 5-hydroxyindoles. J Neurochem. 15:1968;1093-1108.
46. Moller S.E. Plasma neutral amino acids and food preferences. Possible implications in normals and depressives Biblthca Nutr Dieta. 38:1986;149-153.
47. Pardridge W.M. Tryptophan transport through the blood-brain barrier. In vivo measurement of free and albumin-bound amino acid Life Sci. 25:1979;1519-1528.
48. Perry T.L., Hansen S., Christie R.G. Amino compounds and organic acids in CSF, plasma and urine of autistic children. Biol Psychiatry. 13:1978;575-586.
49. Riddle M.A., Anderson G.M., McIntosh S., Harcherick D.F., Shaywitz B.A., Cohen D.J. Cerebrospinal fluid monoamine precursor and metabolite levels in children treated for leukemia. Age and sex effects and individual variability Biol Psychiatry. 21:1986;69-83.
50. Salter M., Pogson C.I. The importance of the liver as a regulator of amino acid supply to the brain. Huether G. Amino Acid Availability and Brain Function in Health and Disease. 1987;21-28 Germany, Springer-Verlag, Berlin.
51. Schain R.J., Freedman D.X. Studies on 5-hydroxyindole metabolism in autistic and other mentally retarded children. J Pediatrics. 58:1996;315-320.
52. Sneddon J.M. Blood platelets as a model for monoamine-containing neurons. Progr Neurobiol. 1:1973;151-198.
53. Stahl S.M. The human platelet. A diagnostic and research tool for the study of biogenic amines in psychiatry and neurologic disorders Arch Gen Psychiatry. 34:1977;509-516.
54. Stahl S.M. Peripheral models for the study of neurotransmitter receptors in man. Psychopharmacol Bull. 21:1985;663-671.
55. Szatmari P. Heterogeneity and the genetics of autism. J Psychiatry Neurosci. 24:1999;159-165.
56. Turnell D., Cooper J. Rapid assay for amino acids in serum or urine by precolumn derivatisation and reversed-phase liquid chromatography. Clin Chem. 28:1982;527-531.
57. Voog L., Eriksson T. Relationship between plasma and brain large neutral amino acids in rats fed diets with different compositions at different times of the day. J Neurochem. 59:1992;1868-1874.
58. Visconti P., Piazzi S., Posar A., Santi A., Pipitone E., Rossi P.G. Amino acids and infantile autism. Dev Brain Dysf. 7:1994;86-92.
59. Weizman A., Gonen N., Tyano S., Szekely G.A., Rehavi M. Platelet [3H]imipramine binding in autism and schizophrenia. Psychopharmacology. 91:1987;101-103.
60. Winsberg B.G., Sverd J., Castells S., Hurwic M., Perel J.M. Estimation of monoamine and cyclic-AMP turnover and amino-acid concentrations of spinal fluid in autistic children. Neuropediatrics. 11:1980;250-255.
61. Young J.G., Cohen D.J., Brown S.L., Caparulo B.K. Decreased urinary free catecholamines in childhood autism. J Am Acad Child Psychiatry. 17:1978;671-678.
62. Young J.G., Cohen D.J., Kavanagh M.E., Landis H.D., Shaywitz B.A., Maas J.W. Cerebrospinal fluid, plasma and urinary MHPG in children. Life Sci. 28:1981;2837-2845.
63. Yuwiler A., Oldendorf W.H., Geller E., Braun L. The effect of albumin binding and amino acid composition on tryptophan uptake into the brain. J Neurochem. 28:1977;1015-1023.